# US 2009/0156420 A1 · Method for detecting cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0156420 A1
- Document ID: US20090156420A1
- Status: Published application
- Kind: A1
- Application number: 12/230,131
- Filed: 2008-08-25
- Published: 2009-06-18
- Earliest claimed: 2000-07-19
- Inventors: Yasuhiro Tsubosa; Kazuhiko Aoyagi; Hiroki Sasaki; Masaaki Terada; Junichi Mineno; Kiyozo Asada; Ikunoshin Kato
- Web page: https://patentgrep.com/patent/US20090156420A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 1/6837: using probe arrays or probe chips (C12Q1/6874 takes precedence)
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

To provide a method for selecting a marker gene useful for cancer classification; a method for classifying cancer using the gene; a method for detecting cancer; a kit usable for the classification method or detection method; and a DNA array carrying the gene. According to the present invention, there can be obtained a gene, wherein expression of the above gene is altered independently from genes each of which expression is altered specifically during cell proliferation and expression level of the above gene is specifically altered depending on every type of cancer samples to be tested, whereby the classification or detection of cancer can be carried out conveniently and quickly without giving surgical treatment. Therefore, the present invention is useful for the diagnosis, the treatment, and the like of cancer.

## Claims

### Claim 1

A method for selecting a gene used as an index of cancer classification based on pathological findings selected from the group consisting of states of infiltration to peripheral tissues, sensitivity against drugs and states of metastasis in lymph nodes, comprising the following steps of:
(1) determining expression levels in cancer samples to be tested for E2F-1 gene and then comparing the determined expression levels with an expression level of the E2F-1 gene in a control sample, thereby evaluating alterations in the expression level of the E2F-1 gene, wherein the control sample is a normal tissue, or a cancer sample with low malignancy;
(2) classifying the cancer samples to be tested into plural numbers of types, based on alterations in expression levels of the E2F-1 gene evaluated in the above step (1) and said pathological findings for the cancer samples to be tested; and
(3) examining alterations in expressions for plural numbers of genes in each of the cancer samples to be tested classified in the above step (2), to select a gene, wherein expression of said gene is altered independently to the E2F-1 gene and expression level of said gene is specifically altered depending on every type of cancer samples to be tested classified in the above step (2);
thereby a gene is selected to be used as an index of cancer classification.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method according to claim 1, wherein in the step (1), an expression level of E2F-1 gene is determined.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the expression levels of genes are determined on the basis of levels of mRNAs transcribed from the genes.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the levels of mRNAs are determined by a hybridization method or a nucleic acid amplification method.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the levels of mRNAs are determined by a DNA array-based hybridization method.

### Claim 7 (depends on 1)

A method for classifying a cancer, wherein the cancer is classified with expression levels of genes in a sample to be tested, the method comprising the following steps:
(a) determining expression levels of at least one of genes used as indices of cancer classification, wherein the genes are selected by the selection method of claim 1, in the sample to be tested, and
(b) comparing the gene expression levels determined in the step (a) with expression levels of the same genes in a control sample, thereby classifying cancer for the sample to be tested.

### Claim 8 (depends on 7)

The method according to claim 7, wherein in the step (a), expression levels of at least 5 kinds of genes are determined.

### Claim 9 (depends on 7, 8)

The method of according to claim 7 or 8, wherein the expression levels of genes are determined on the basis of levels of mRNAs transcribed from the gene, or levels of polypeptides translated from the genes.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the levels of mRNAs are determined by a hybridization method or a nucleic acid amplification method.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the levels of mRNAs are determined by a DNA microarray-based hybridization method.

### Claim 12 (depends on 9)

The method according to claim 9, the levels of the polypeptides are determined by using antibodies capable of binding specifically to the polypeptides or fragments thereof.

### Claim 13 (depends on 8)

The method according to claim 8, wherein expression levels of at least 5 kinds of genes selected from the following Group I and/or expression levels of at least 5 kinds of genes selected from the following Group II are determined:
Group I:
insulin-like growth factor binding protein 2 (IGFBP2) gene, (GenBank accession number: X16302);
BIGH3 gene (GenBank accession number: M77349);
insulin-like growth factor binding protein 6 (IGFBP6) gene, (GenBank accession number: M62402);
gelatinase A (MMP-2) gene; (GenBank accession number: M55593);
type II cytoskeletal 7 keratin (cytokeratin 7 (K7; CK 7)) gene, (GenBank accession number: M13955);
desmoplakin I gene, (GenBank accession number: M77830);
glutathione S-transferase A1 gene, (GenBank accession number: M116594);
glutathione S-transferase Pi (GSTP1) gene, (GenBank accession number: U12472);
collagenase-3 (MMP-13) gene, (GenBank accession number: X75308);
type II cytoskeletal 5 keratin (cytokeratin 5 (K5; CK 5)) gene, (GenBank accession number: M21389);
P-cadherin gene, (GenBank accession number: X63629);
type I cytoskeletal 14 keratin (cytokeratin 14 (K14 CK 14)) gene, (GenBank accession number: J00124);
type II cytoskeletal 6 kerain (cytokeratin 6B (CK 6B)) gene, (GenBank accession number: L42610);
matrilysin (MMP-7) gene, (GenBank accession number: X07819);
forkhead-like 7 gene, (GenBank accession number: AF048693);
connective tissue growth factor (CTGF) gene, (GenBank accession number: M92934);
growth hormone-dependent insulin-like growth factor-binding protein gene, (GenBank accession number: M35878); and
Rho8 protein gene, (GenBank accession number: X95282);
Group II:
RBA/p48 gene, (GenBank accession number: X74262);
cell division control protein 2 homolog (EC 2.7.1.-) (cdc2) gene, (GenBank accession number: X05360);
replication factor C 38-kDa subunit (RFC38) gene, (GenBank accession number: L07541);
apopain precursor gene, (GenBank accession number: U13737);
xeroderma pigmentosum group C repair complementing protein p58/HHR23B gene, (GenBank accession number: D21090);
cyclin G2 gene, (GenBank accession number: U47414);
cyclin A gene, (GenBank accession number: X51688);
apoptosis-related protein TFAR15 gene, (GenBank accession number: AF022385);
TRKB tyrosine kinase receptor gene, (GenBank accession number: U12140);
gene for signal transducer and activator of transcription 1-alpha/beta (STAT1), (GenBank accession number: M97935);
K-ras oncogene, (GenBank accession number: M54968);
retinoblastoma susceptibility protein (RB1) gene, (GenBank accession number: L41870);
gene for BCL2/adenovirus E1B 19 kD-interacting protein 1 (BNIP1) mRNA, complete cds, (GenBank accession number: AF083957); and
inhibitor of apoptosis protein 1 (HIAP-1) gene, (GenBank accession number: U45878).

### Claim 14 (depends on 7, 8)

The method according to claim 7 or 8, wherein a sample to be tested is classified on the basis of risk for metastasis into a lymph node.

### Claim 15 (depends on 1)

A method for detecting cancer, comprising the following steps:
(1) determining expression levels of at least one of genes used as indices of cancer classification in a sample to be tested, wherein the genes are selected by the selection method of claim 1, and
(2) comparing the expression levels of genes in the sample to be tested determined in the step (1) with expression levels of the genes in a control sample, thereby detecting cancer,
wherein expressions of nucleic acids corresponding to at least one of the genes or expressions of polypeptides encoded by at least one of the genes used as indices of cancer classification are altered compared with a control sample is an index of the presence of cancer cells in the sample to be tested.

### Claim 16 (depends on 15)

The method according to claim 15, wherein in the step (1), expression levels of at least 5 kinds of genes are determined.

### Claim 17 (depends on 15, 16)

The method according to claim 15 or 16, wherein the expression levels of genes are determined on the basis of levels of mRNAs transcribed from the genes, or levels of polypeptides translated from the genes.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the levels of mRNAs are determined by a hybridization method or a nucleic acid amplification method.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the levels of mRNAs are determined by a DNA microarray-based hybridization method.

### Claim 20 (depends on 17)

The method according to claim 17, wherein the levels of polypeptides are determined by using antibodies capable of binding specifically to the polypeptides or fragments thereof.

### Claim 21 (depends on 13, 15)

The method according to claim 15, wherein expression levels of at least 5 kinds of genes selected from Group I of claim 13, and/or expression levels of at least 5 kinds of genes selected from genes of Group II of claim 13 are determined.

### Claim 22 (depends on 13)

A kit usable for classification and/or detection of cancer, comprising primers and/or a probe which is usable for determining expression levels of at least 5 kinds of genes selected from genes of Group I of claim 13, and/or expression levels of at least 5 kinds of genes selected from genes of Group II of claim 13.

### Claim 23 (depends on 22)

The kit according to claim 22, wherein each of the primers is an oligonucleotide having at least 15 to 40 nucleotides in length.

### Claim 24 (depends on 22)

The kit according to claim 22, wherein the probe is an oligonucleotide having at least 15 nucleotides in length.

### Claim 25 (depends on 22)

The kit according to claim 22, said kit further comprising reagents for gene amplification.

### Claim 26 (depends on 13)

A kit usable for classification and/or detection of cancer, comprising to antibodies capable of binding specifically to polypeptides encoded by at least 5 kinds of genes selected from genes of Group I of claim 13, and/or antibodies capable of binding specifically to polypeptides encoded by at least 5 kinds of genes selected from genes of Group II of claim 13.

### Claim 27 (depends on 13)

A DNA array usable for classification and/or detection of cancer, wherein at least 5 kinds of genes selected from genes of Group I of claim 13 or fragments thereof, and/or at least 5 kinds of genes selected from genes of Group II of claim 13 or fragments thereof are immobilized at each of defined regions on a support.

### Claim 28 (depends on 27)

The DNA array according to claim 27, wherein the support is a non-porous support.

### Claim 29 (depends on 28)

The DNA array according to claim 28, wherein the support is a glass.

### Claim 30 (depends on 1)

The method according to claim 1, wherein a selected gene is used as an index of esophageal cancer classification.
